Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,648 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,489)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00378573 | Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | terminated | Phase 2 | 17 | SanofiINDUSTRY | 1 | Jan 26, 2010 | clinicaltrials |
| NCT00264134 | Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 40 | Kentuckiana Cancer InstituteOTHER | 1 | Jan 20, 2010 | clinicaltrials |
| NCT00494026 | Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC) | terminated | Phase 2 | 4 | Eli Lilly and CompanyINDUSTRY | 4 | Nov 20, 2009 | clinicaltrials |
| NCT00447421 | A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy | terminated | Phase 1 / Phase 2 | 9 | Eli Lilly and CompanyINDUSTRY | 2 | Oct 28, 2009 | clinicaltrials |
| NCT00313768 | Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC | terminated | Phase 2 | 23 | PfizerINDUSTRY | 1 | Sep 28, 2009 | clinicaltrials |
| NCT00321308 | Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 36 | PfizerINDUSTRY | 3 | Sep 28, 2009 | clinicaltrials |
| NCT00273507 | Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and IIIA/T3 | terminated | Phase 3 | 270 | Rigshospitalet, DenmarkOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00461110 | A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC) | terminated | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 4, 2009 | clinicaltrials |
| NCT00434226 | A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L) | terminated | Phase 2 | 56 | Genentech, Inc.INDUSTRY | 0 | Aug 21, 2009 | clinicaltrials |
| NCT00558922 | A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 54 | Aegera TherapeuticsINDUSTRY | 1 | Jul 30, 2009 | clinicaltrials |
| NCT00532025 | Sorafenib in Resected Non-small Cell Lung Carcinoma(SIRN) | terminated | Phase 2 | 134 | Johannes Gutenberg University MainzOTHER | 1 | Jul 28, 2009 | clinicaltrials |
| NCT00234442 | Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer | terminated | Phase 2 | 47 | AstraZenecaINDUSTRY | 1 | Jun 30, 2009 | clinicaltrials |
| NCT00522639 | Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation(FDG-PET lung) | terminated | Phase 3 | 120 | Maastricht Radiation OncologyOTHER | 1 | Jun 30, 2009 | clinicaltrials |
| NCT00383331 | Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer | terminated | Phase 2 | 19 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 3, 2009 | clinicaltrials |
| NCT00259285 | Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer | terminated | Phase 2 | 10 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 2, 2009 | clinicaltrials |
| NCT00475657 | Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer | terminated | Phase 2 | 5 | Eli Lilly and CompanyINDUSTRY | 1 | May 29, 2009 | clinicaltrials |
| NCT00435578 | Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma | terminated | Phase 2 | 50 | Threshold PharmaceuticalsINDUSTRY | 1 | Apr 30, 2009 | clinicaltrials |
| NCT00174369 | MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 34 | PfizerINDUSTRY | 1 | Mar 17, 2009 | clinicaltrials |
| NCT00585845 | Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment | terminated | Phase 1 | 17 | Anza Therapeutics, Inc.INDUSTRY | 2 | Feb 20, 2009 | clinicaltrials |
| NCT00161278 | Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling | terminated | Phase 2 | 1 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 30, 2008 | clinicaltrials |
| NCT00535015 | Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer | terminated | Phase 2 | 70 | AnaborexINDUSTRY | 2 | Jul 22, 2008 | clinicaltrials |
| NCT00607425 | Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening(SPIT-LC) | terminated | — | 40 | Scottsdale HealthcareOTHER | 0 | Jul 17, 2008 | clinicaltrials |
| NCT00263016 | Docetaxel in Non Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 50 | SanofiINDUSTRY | 1 | Mar 20, 2008 | clinicaltrials |
| NCT00098917 | Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer | terminated | Phase 1 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 28, 2008 | clinicaltrials |
| NCT00215748 | Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Receiving Weekly Docetaxel | terminated | Phase 2 | 40 | Geriatric Oncology ConsortiumOTHER | 1 | Nov 16, 2007 | clinicaltrials |
| NCT00061646 | Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 25 | AbbottINDUSTRY | 1 | Aug 14, 2007 | clinicaltrials |
| NCT00243204 | Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy | terminated | Phase 3 | 400 | Point TherapeuticsINDUSTRY | 1 | Jun 8, 2007 | clinicaltrials |
| NCT00290017 | Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy | terminated | Phase 3 | 400 | Point TherapeuticsINDUSTRY | 1 | Jun 8, 2007 | clinicaltrials |
| NCT00316433 | Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer | terminated | Phase 2 | 24 | Swedish Medical CenterOTHER | 1 | Apr 5, 2007 | clinicaltrials |
| NCT00420862 | The DANTE Trial. A Randomized Study on Lung Cancer Screening With Low-Dose Spiral Computed Tomography | terminated | Phase 3 | 2,400 | Istituto Clinico HumanitasOTHER | 1 | Jan 11, 2007 | clinicaltrials |
| NCT00064636 | Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | terminated | Phase 1 | 46 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Jan 26, 2010source: clinicaltrials